Efficacy and safety of Shenlingbaizhusan as adjuvant therapy for gastric cancer: a meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

CHEN Dongping , CHEN Xiaofan , ZHOU Xu , YAN Dongmei , NIE Heyun , YU Xinyu , CHEN Qisheng ,  ZHU Weifeng

Evidence-based Medicine Research Center, Jiangxi University of Traditional Chinese Medicine, Nanchang, 330004, P.R.China;

Corresponding author：

ZHU Weifeng, Email: zwf0322@126.com

Keywords：

Shenlingbaizhusan; Gastric cancer; meta-analysis; Systematic review; Randomized controlled trial

DOI：

10.7507/1672-2531.201809089

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objectives To systematically review the efficacy and safety of Shenlingbaizhusan as adjuvant therapy for gastric cancer.Methods PubMed, EMbase, The Cochrane Library, CNKI, WanFang Data, VIP and CBM databases were electronically searched to collect randomized controlled trials (RCTs) on efficacy and safety of Shenlingbaizhusan as adjuvant therapy for gastric cancer from inception to July 31^st, 2018. Two reviewers independently screened literature, extracted data and assessed risk of bias of included studies, then, meta-analysis was performed by using RevMan 5.3 software.Results A total of 14 RCTs involving 1 142 patients were included. The results of meta-analysis showed that: compared with control group, Shenlingbaizhusan could improve the efficiency of gastric cancer patients (RR=1.55, 95%CI 1.31 to 1.84, P<0.000 01) and the living quality of patients (RR=1.70, 95%CI 1.39 to 2.07, P<0.000 01), and reduce the side effects such as nausea, vomiting, diarrhea and the the possibilities of recurrence. However there was no difference between two groups in bone marrow suppression.Conclusions The current evidence shows that Shenlingbaizhusan as adjuvant therapy has better curative effect on gastric cancer, which can improve the efficiency of treatment and quality of life, and reduce some adverse reactions of chemotherapy. Due to limited quality and quantity of the included studies, more high quality studies are needed to verify above conclusions.

Citation： CHEN Dongping, CHEN Xiaofan, ZHOU Xu, YAN Dongmei, NIE Heyun, YU Xinyu, CHEN Qisheng, ZHU Weifeng. Efficacy and safety of Shenlingbaizhusan as adjuvant therapy for gastric cancer: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2019, 19(4): 457-463. doi: 10.7507/1672-2531.201809089 Copy

1.	Todd A, Groundwater PW, Gill JH. The global burden of cancer. anticancer therapeutics: from drug discovery to clinical applications. New York: John Wiley & Sons, 2017.
2.	刘健. 胃癌高发地区高危人群胃癌癌前疾病的危险因素调查、干预措施及综合防治效果流行病学评价. 沈阳: 中国医科大学, 2010.
3.	李岩, 林三仁. 2005 年全国消化道肿瘤诊治及研究进展学术会议纪要. 中华消化杂志, 2005, 25(10): 631-633.
4.	冯天保, 陶双友. 加味麦门冬汤治疗肿瘤放化疗后消化道反应 38 例. 中国民间疗法, 2012, 20(7): 34-35.
5.	Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials, 2009, 10: 46.
6.	胡良平. 我国临床科研的现状与思考. 中国医学论坛报, 2006.02.16.
7.	丁婕, 戴旭, 孟宪运, 等. 实体瘤疗效评价标准的研究进展. 中国肿瘤临床与康复, 2015, 22(9): 1150-1152.
8.	Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions (Version 5.1.0). The Cochrane Collaboration, 2011. Available at: http://www.cochrane-handbook.org.
9.	李彦丽. 大剂量参苓白术散加减对胃癌术后化疗耐受性及生命质量的影响. 光明中医, 2017, 32(21): 3100-3102.
10.	徐力, 薛恬, 刘沈林, 等. 参苓白术散联合 TS 化疗方案治疗进展期胃癌 50 例临床观察. 中医杂志, 2016, 57(16): 1393-1396.
11.	郭小培. 参苓白术散加减联合化疗治疗中晚期胃癌疗效观察. 世界最新医学信息文摘, 2016, 16(40): 96, 99.
12.	贾磊, 张跃强. 参苓白术散加减联合化疗方案治疗胃癌 59 例. 中国民间疗法, 2017, 25(11): 55-56.
13.	李自强. 参苓白术散加减配合化疗治疗中晚期胃癌 27 例. 陕西中医, 2011, 32(1): 4-6.
14.	赵月宏. 参苓白术散加减与化疗治疗中晚期胃癌的效果研究. 中国农村卫生, 2018, (2): 90.
15.	陈卓, 程祺, 唐海波, 等. 参苓白术散加减和化疗治疗中晚期胃癌临床有效率及不良反应发生率. 家庭医药·就医选药, 2017, (11): 58.
16.	邵扣凤, 肖平. 参苓白术散加减方对晚期胃癌化疗患者化疗副作用及免疫功能的影响. 中医药导报, 2016, 22(8): 26-28, 32.
17.	王晓华, 周强, 刘晓梅. 参苓白术散联合西药治疗胃癌的临床效果观察. 实用癌症杂志, 2014, 29(11): 1464-1466.
18.	袁涛. 参苓白术散联合化疗治疗进展期胃癌的临床观察. 光明中医, 2017, 32(10): 1490-1491.
19.	张红, 苏志新. 参苓白术散加味防治中晚期胃癌化疗所致毒副反应的临床观察. 湖南中医药大学学报, 2008, 28(2): 51-53, 56.
20.	张阳阳. 参苓白术散联合化疗治疗胃癌患者的临床疗效. 中国药物经济学, 2017, 12(9): 39-41.
21.	陈友新. 参苓白术散加减对胃癌术后常见并发症的疗效观察. 中国医药指南, 2016, 14(21): 195-196.
22.	郭兆平, 陈泽民. 参苓白术散加减治疗胃癌术后消化不良. 肿瘤防治研究, 2005, 32(9): 601-601.
23.	太平惠民和剂局. 太平惠民和剂局方. 北京: 人民卫生出版社, 2007.
24.	呼永华, 张慧芳. 参苓白术散对小细胞肺癌患者行 EP 方案化疗胃肠道反应的疗效观察. 甘肃医药, 2013, 32(11): 817-818.
25.	王华新, 刘文娟. 白术在胃肠道疾病方面的药理与临床应用. 时珍国医国药, 2007, 18(11): 2847-2848.
26.	黄凯庭, 周淑芳, 吴世芳, 等. 参苓白术散组方浅析及在脾虚湿盛证中的应用. 河北中医, 2012, 34(10): 1495-1496.

1. Todd A, Groundwater PW, Gill JH. The global burden of cancer. anticancer therapeutics: from drug discovery to clinical applications. New York: John Wiley & Sons, 2017.
2. 刘健. 胃癌高发地区高危人群胃癌癌前疾病的危险因素调查、干预措施及综合防治效果流行病学评价. 沈阳: 中国医科大学, 2010.
3. 李岩, 林三仁. 2005 年全国消化道肿瘤诊治及研究进展学术会议纪要. 中华消化杂志, 2005, 25(10): 631-633.
4. 冯天保, 陶双友. 加味麦门冬汤治疗肿瘤放化疗后消化道反应 38 例. 中国民间疗法, 2012, 20(7): 34-35.
5. Wu T, Li Y, Bian Z, et al. Randomized trials published in some Chinese journals: how many are randomized? Trials, 2009, 10: 46.
6. 胡良平. 我国临床科研的现状与思考. 中国医学论坛报, 2006.02.16.
7. 丁婕, 戴旭, 孟宪运, 等. 实体瘤疗效评价标准的研究进展. 中国肿瘤临床与康复, 2015, 22(9): 1150-1152.
8. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions (Version 5.1.0). The Cochrane Collaboration, 2011. Available at: http://www.cochrane-handbook.org.
9. 李彦丽. 大剂量参苓白术散加减对胃癌术后化疗耐受性及生命质量的影响. 光明中医, 2017, 32(21): 3100-3102.
10. 徐力, 薛恬, 刘沈林, 等. 参苓白术散联合 TS 化疗方案治疗进展期胃癌 50 例临床观察. 中医杂志, 2016, 57(16): 1393-1396.
11. 郭小培. 参苓白术散加减联合化疗治疗中晚期胃癌疗效观察. 世界最新医学信息文摘, 2016, 16(40): 96, 99.
12. 贾磊, 张跃强. 参苓白术散加减联合化疗方案治疗胃癌 59 例. 中国民间疗法, 2017, 25(11): 55-56.
13. 李自强. 参苓白术散加减配合化疗治疗中晚期胃癌 27 例. 陕西中医, 2011, 32(1): 4-6.
14. 赵月宏. 参苓白术散加减与化疗治疗中晚期胃癌的效果研究. 中国农村卫生, 2018, (2): 90.
15. 陈卓, 程祺, 唐海波, 等. 参苓白术散加减和化疗治疗中晚期胃癌临床有效率及不良反应发生率. 家庭医药·就医选药, 2017, (11): 58.
16. 邵扣凤, 肖平. 参苓白术散加减方对晚期胃癌化疗患者化疗副作用及免疫功能的影响. 中医药导报, 2016, 22(8): 26-28, 32.
17. 王晓华, 周强, 刘晓梅. 参苓白术散联合西药治疗胃癌的临床效果观察. 实用癌症杂志, 2014, 29(11): 1464-1466.
18. 袁涛. 参苓白术散联合化疗治疗进展期胃癌的临床观察. 光明中医, 2017, 32(10): 1490-1491.
19. 张红, 苏志新. 参苓白术散加味防治中晚期胃癌化疗所致毒副反应的临床观察. 湖南中医药大学学报, 2008, 28(2): 51-53, 56.
20. 张阳阳. 参苓白术散联合化疗治疗胃癌患者的临床疗效. 中国药物经济学, 2017, 12(9): 39-41.
21. 陈友新. 参苓白术散加减对胃癌术后常见并发症的疗效观察. 中国医药指南, 2016, 14(21): 195-196.
22. 郭兆平, 陈泽民. 参苓白术散加减治疗胃癌术后消化不良. 肿瘤防治研究, 2005, 32(9): 601-601.
23. 太平惠民和剂局. 太平惠民和剂局方. 北京: 人民卫生出版社, 2007.
24. 呼永华, 张慧芳. 参苓白术散对小细胞肺癌患者行 EP 方案化疗胃肠道反应的疗效观察. 甘肃医药, 2013, 32(11): 817-818.
25. 王华新, 刘文娟. 白术在胃肠道疾病方面的药理与临床应用. 时珍国医国药, 2007, 18(11): 2847-2848.
26. 黄凯庭, 周淑芳, 吴世芳, 等. 参苓白术散组方浅析及在脾虚湿盛证中的应用. 河北中医, 2012, 34(10): 1495-1496.

Chinese Journal of Evidence-Based Medicine

Efficacy and safety of Shenlingbaizhusan as adjuvant therapy for gastric cancer: a meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content